Just prior to publication of this issue, the FDA approved direct-to-inject administration of cabotegravir/rilpivirine (Cabenuva), without an initial oral lead-in period. This is an update from the information Dr. Tanyaporn Wansom presents in this issue, and means that as of March 24, 2022, it is appropriate to consider initiation of injectable long-acting cabotegravir and rilpivirine without first giving pills of the drugs to confirm tolerability. Learners are advised to review the updated Cabenuva prescribing information for additional guidance.
Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting ART actually mean in practice?
Join us for this eHIV Review podcast, as Dr. Tanyaporn Wansom, Senior Infectious Diseases Consultant at Chayun Consulting in Bangkok Thailand, takes us to the clinic to answer some of these key questions.
Senior Infectious Diseases Consultant
Nurse Educator – Office Based Addiction Treatment, Training and Technical Assistance Program
Boston Medical Center
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: April 14, 2022
Expiration date: April 13, 2024